Dr. Reddys and P-Pharm: Redditux (INN rituximab)

The main articles are:

• Lymphoma
• Rheumatoid arthritis

Redditux is a biosimilar of rituximab, the first monoclonal antibody approved for use in oncology. This chimeric antibody has a targeted effect on the CD20 protein found on the surface of malignant and normal B cells, but does not affect B cell precursors, mature plasma cells, or other normal tissues. Rituximab had a significant impact on the treatment of various B-cell

2025: Localization in Russia

Dr. Reddy's, part of Dr. Reddy's global pharmaceutical company headquartered in Hyderabad, India, and the R-Farm Group have announced the completion of localization of the full-cycle production of the biotechnological drug Redditux (INN rituximab) starting from the substance stage in Russia. The drug has been registered in Russia since 2016. R-Pharm announced this on January 14, 2025.

Redditux is indicated in targeted therapy of non-Hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis. It is included in the list of drugs used under the state program of 14 high-cost nosologies, which guarantees the provision of vital medicines to patients with rare and socially significant diseases.

Dr. Reddy's has been operating in Russia for more than 30 years and all this time strives to increase the availability of innovative medicines for patients, guided by the mission "Health cannot wait." The localization of the biotechnological drug Redditux from the stage of substance production is a vivid example of the implementation of our approach and will help provide the necessary drug for Russian patients with life-threatening diseases, "said Vasily Pavlov, CEO of Dr. Reddy's in Russia.

In 2017, we localized the production of the finished dosage form at the facilities of the R-Pharm group of companies. As of January 2025, the project received its development - the production of a full-cycle drug was established at the Sputnik Technopolice plant "," one of the biotechnological enterprises in the territory. Russia The project meets the tasks Governments of localizing the most important drugs health care and the pharmaceutical development strategy until industries RUSSIAN FEDERATION 2030, - said the Vasily Ignatiev general director of R-Pharm.